Morgan Stanley Calliditas Therapeutics Ab Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$17.65 - $41.41 $89,432 - $209,824	-5,067 Reduced 84.65%	919 $35,000
Q2 2024 Aug 14, 2024	SELL	$17.65 - $41.41 $89,432 - $209,824	-5,067 Reduced 84.65%	919 $35,000
Q1 2024 Oct 17, 2024	BUY	$20.04 - $25.66 $101,542 - $130,019	5,067 Added 551.36%	5,986 $125,000
Q1 2024 Aug 16, 2024	BUY	$20.04 - $25.66 $107,895 - $138,153	5,384 Added 894.35%	5,986 $125,000
Q1 2024 May 15, 2024	BUY	$20.04 - $25.66 $107,895 - $138,153	5,384 Added 894.35%	5,986 $125,000
Q4 2023 Aug 16, 2024	SELL	$15.79 - $28.99 $5,005 - $9,189	-317 Reduced 34.49%	602 $15,000
Q4 2023 Feb 13, 2024	SELL	$15.79 - $28.99 $27,253 - $50,036	-1,726 Reduced 74.14%	602 $15,000
Q3 2023 Nov 15, 2023	SELL	$15.68 - $20.38 $5,143 - $6,684	-328 Reduced 12.35%	2,328 $42,000
Q2 2023 Aug 14, 2023	BUY	$15.7 - $25.61 $19,923 - $32,499	1,269 Added 91.49%	2,656 $42,000
Q1 2023 May 15, 2023	SELL	$16.8 - $25.24 $856 - $1,287	-51 Reduced 3.55%	1,387 $33,000
Q4 2022 Feb 14, 2023	BUY	$11.5 - $19.6 $3,507 - $5,978	305 Added 26.92%	1,438 $24,000
Q3 2022 Nov 14, 2022	SELL	$14.12 - $22.49 $44,647 - $71,113	-3,162 Reduced 73.62%	1,133 $18,000
Q2 2022 Oct 27, 2022	BUY	$12.85 - $20.36 $45,823 - $72,603	3,566 Added 489.16%	4,295 $76,000
Q2 2022 Aug 15, 2022	BUY	$12.85 - $20.36 $45,823 - $72,603	3,566 Added 489.16%	4,295 $76,000
Q1 2022 Oct 27, 2022	SELL	$15.14 - $25.55 $53,989 - $91,111	-3,566 Reduced 83.03%	729 $14,000
Q1 2022 May 13, 2022	SELL	$15.14 - $25.55 $30,673 - $51,764	-2,026 Reduced 73.54%	729 $14,000
Q4 2021 Feb 14, 2022	BUY	$15.04 - $26.32 $11,280 - $19,740	750 Added 37.41%	2,755 $69,000
Q3 2021 Nov 15, 2021	BUY	$21.03 - $33.19 $42,165 - $66,545	2,005 New	2,005 $43,000

Others Institutions Holding CALT

# of Institutions

Shares Held

1.84K

Call Options Held

Put Options Held

View Full List

About Calliditas Therapeutics AB

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

More about CALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account